Large Diameter Advanta™ V12 Covered Stent Trial for Coarctation of the Aorta

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

70 participants

Study Classification

INTERVENTIONAL

Study Start Date

2009-09-30

Study Completion Date

2017-04-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study is designed as a prospective, multicenter, non-randomized, single arm study to assess the safety and effectiveness of the Large Diameter Advanta™ V12 Covered Stent for stent implantation in coarctations of the aorta.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Coarctation Of the Aorta Stent Trial

NCT00552812

Coarctation of the Aorta

COMPLETED NA

Endurant Stent Graft System vs Excluder Endoprothesis: ADVANCE Trial

NCT05378347

Abdominal Aortic Aneurysm Abdominal Aortic Aneurysm >= 5.5 Centimeters in Male (Disorder) Abdominal Aortic Aneurysm >= 5.0 Centimeters in Female (Disorder)

RECRUITING NA

DARTS I: Feasibility, Safety, and Performance Trial

NCT03397251

Acute DeBakey I Aortic Dissection Intramural Hematoma

COMPLETED NA

Endovascular Repair of Descending Thoracic Aortic Aneurysms

NCT00802984

Aortic Aneurysm, Thoracic

COMPLETED PHASE4

Post-Approval Clinical Study of the Talent Thoracic Stent Graft to Treat Thoracic Aortic Aneurysms (THRIVE)

NCT00805948

Thoracic Aortic Aneurysms

TERMINATED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The performance metric for comparison is based on data from the Congenital Cardiovascular Interventional Study Consortium (CCISC) as reported by Golden and Hellenbrand \[1\]. The CCISC experience from 1989 to 2005 shows a true procedural success rate of 98.6%.

The patient population will be subjects with coarctation of the aorta. A total of 70 subjects, children, adolescents and adults, will be enrolled at up to 15 study sites. Baseline clinical and angiographic assessment will determine the subject's eligibility for enrollment in the study. Subjects will continue in the study for long term annual follow-up through 3, 4, and 5 years.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Coarctation of the Aorta

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Investigational Group

Use of Large Diameter Advanta™ V12 Covered Stent.

Group Type EXPERIMENTAL

Large Diameter Advanta™ V12 Covered Stent

Intervention Type DEVICE

Stent placement

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Large Diameter Advanta™ V12 Covered Stent

Stent placement

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients with a presence of native or recurrent coarctation of the aorta as confirmed by blood pressure gradient, 2D-echocardiography with Doppler or angiography.
* Subject weighs a minimum of 30 kg.
* The peak pressure gradient is ≥20 mmHg systolic blood pressure across the coarctation site.
* Vessels at access site can accept a minimum size of 9 French for a 12 mm balloon and 11 French for a 14 and 16 mm balloon.
* Coarctation can be successfully crossed with a guide wire, sheath and device.
* Diameter of transverse arch distal to left subclavian artery is between 9.5 mm and 20 mm in diameter.
* Subject is able and willing to adhere to all required follow-up visits and testing.
* Subject is able and willing to adhere to the required follow-up medication regimen.

Exclusion Criteria

* The physician is not able to access the coarctation with standard techniques.
* Presence of other thoracic aortic arterial lesions or aneurysms requiring treatment within 30 days of the implant procedure.
* Length of coarctation is greater than 45 mm in length.
* Connective tissue and genetic disorders, including William, Marfan, Turner, Noonan syndrome.
* The coarctation has adjacent, acute thrombus.
* The coarctation was previously treated with a stent.
* Proximity of the coarctation to an important side branch resulting in crossing of the side branch with the Large Diameter Advanta™ V12 Covered Stent device (e.g. "jailing" of the branch vessel).
* Subject has a tubular graft, interposition graft, stent graft at or near the coarctation site that would be interfere with delivery, positioning, expansion or stabilization of the Large Diameter Advanta™ V12 Covered Stent
* Subject has contrast agent hypersensitivity that cannot be adequately premedicated, has a hypersensitivity to stainless steel, expanded polytetrafluoroethylene (ePTFE) or has intolerance to antiplatelet, anticoagulant, or thrombolytic medications.
* Bloodstream infection
* Subject is pregnant or breastfeeding.
* Subject has a co-morbid illness that may result in a life expectancy of less than 1 year.
* The investigator deems the subject to be an inappropriate candidate for the study.
* Subject is participating in an investigational study of a new drug, biologic or device at the time of study screening. NOTE: Subjects who are participating in the long term follow-up phase of a previously investigational and now approved product are not excluded by this criterion.

Eligible Sex

ALL

Accepts Healthy Volunteers

No